Phase III Open Label First Line Therapy Study of Tislelizumab With Chemotherapy Versus Chemotherapy in Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(NSCLC)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 12 Nov 2019 According to a BeiGene media release, top-line results are expected in 2020.
- 23 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2018 New trial record